2024-03-28T19:49:13Zhttp://digital.csic.es/dspace-oai/requestoai:digital.csic.es:10261/1355032022-07-01T11:25:24Zcom_10261_64com_10261_1col_10261_1325
Treatment of chagas disease
Kahnberg, Pia
Johansson, N.G.
Gilbert, Ian H.
Hampton, Shahienaz
Harrison, Justin
Sarkar, Sandipan
González-Pacanowska, D.
The invention provides compounds of the formula: wherein L1 and L2 are independently selected from O and S; R1 is C3-C6straight or branched alkyl, C3-C7cycloalkyl, C5-C7cycloalkenyl, adamantly, phenyl or saturated heterocyclyl, any of which being optionally substituted; R2 is H, methyl or ethyl; R5 is NRxCORy, NRxRy, CH2COCH3, CH2C≡N, or a 5- or 6-membered heteroaryl group which is optionally substituted; X, Y and Z are independently N or CH; Rx is independently H or C1-C4alkyl; Ry is independently H, CrC4alkyl, phenyl or benzyl, either of which is optionally substituted; n is 0-3; salts, hydrates and N-oxides, wherein the optional substituents are further defined in the claims. The compounds have utility in the prophylaxis or treatment of trypanosomal diseases, such as T. cruzi (Chagas disease).
Peer reviewed
University of Dundee, Medivir AB, Consejo Superior de Investigaciones Científicas (España), Swiss Tropical and Public Health Institute, Syngene International Limited PLC
A1 Solicitud de patente con informe sobre el estado de la técnica
2016-08-11T11:23:17Z
2016-08-11T11:23:17Z
2015-12-17
2015-06-09
solicitud de patente
WO2015189595 A1
http://hdl.handle.net/10261/135503
PCT/GB2015/051683
en
Sí
open